TransMedics TMDX
$85.25 −$8.77 (-9.33%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $85.60 +0.41%
Open$90.81
Prev close$94.02
Day range$83.89 – $91.62
Volume1.59M
Market cap$2.96B
P/E (TTM)23.2
Dividend yield–
TMDX Stock News
Headlines matching TransMedics or the TMDX ticker, most recent first.
- Needham Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $106
- Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $90 Negative
- Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Raises Target Price to $100 Positive
- GUIDANCE: (TMDX) TransMedics Expects Full Year 2026 Revenue Range $737M - $757M, Vs. FactSet Est of $743.1M
- A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $95 to $106
- A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $95 to $122
- Needham Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $106 Negative
- TransMedics (TMDX): Buy Rating Backed by Accelerating U.S. Organ Transplant Volumes and Expanding OCS Utilization
- Oppenheimer Maintains TransMedics(TMDX.US) With Hold Rating
- CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $95
- Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $120 Negative
- Evercore Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $90 Negative
- Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $120
- CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $124
- Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Aquestive Therapeutics (AQST) and Alto Neuroscience, Inc. (ANRO)
No comments yet — be the first to weigh in on TMDX.
Sign in to join the discussion.